$TPST
Tempest Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023061278 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.331M $2.370M
YoY Change 6.08% -15.3%
% of Gross Profit
Research & Development $4.183M $4.221M
YoY Change -27.8% -29.33%
% of Gross Profit
Depreciation & Amortization $85.00K $88.00K
YoY Change -60.83% -56.22%
% of Gross Profit
Operating Expenses $7.514M $4.221M
YoY Change -15.89% -29.33%
Operating Profit -$6.592M
YoY Change -24.84%
Interest Expense $26.00K $373.0K
YoY Change -106.02% -4.11%
% of Operating Profit
Other Income/Expense, Net -$194.0K
YoY Change 10.23%
Pretax Income -$7.488M -$6.790M
YoY Change -17.74% -24.11%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$7.488M -$6.786M
YoY Change -17.74% -24.15%
Net Earnings / Revenue
Basic Earnings Per Share -$0.48
Diluted Earnings Per Share -$0.38 -$0.48
COMMON SHARES
Basic Shares Outstanding 19.25M 13.32M
Diluted Shares Outstanding 14.12M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.23M $11.10M
YoY Change 25.62% -74.06%
Cash & Equivalents $39.23M $11.10M
Short-Term Investments
Other Short-Term Assets $1.133M $232.0K
YoY Change 330.8% -75.19%
Inventory
Prepaid Expenses $700.0K $751.0K
Receivables
Other Receivables
Total Short-Term Assets $40.36M $12.29M
YoY Change 22.5% -79.6%
LONG-TERM ASSETS
Property, Plant & Equipment $10.79M $921.0K
YoY Change 918.11% 0.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $448.0K $393.0K
YoY Change 4.43% -42.46%
Total Long-Term Assets $11.24M $11.70M
YoY Change -14.45% 301.37%
TOTAL ASSETS
Total Short-Term Assets $40.36M $12.29M
Total Long-Term Assets $11.24M $11.70M
Total Assets $51.60M $23.99M
YoY Change 11.96% -62.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $845.0K $1.139M
YoY Change -23.74% 23.14%
Accrued Expenses $4.281M $1.995M
YoY Change 44.58% -22.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.285M $2.134M
YoY Change -39.03%
Total Short-Term Liabilities $9.411M $7.422M
YoY Change 29.33% -69.15%
LONG-TERM LIABILITIES
Long-Term Debt $6.264M $8.371M
YoY Change -39.6% -29.28%
Other Long-Term Liabilities $9.160M $9.400M
YoY Change -11.33% 1768.79%
Total Long-Term Liabilities $15.42M $8.371M
YoY Change 48.72% -29.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.411M $7.422M
Total Long-Term Liabilities $15.42M $8.371M
Total Liabilities $24.84M $25.18M
YoY Change -11.23% -30.83%
SHAREHOLDERS EQUITY
Retained Earnings -$165.3M -$157.8M
YoY Change 21.72% 24.56%
Common Stock $22.00K $14.00K
YoY Change 100.0% 40.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.77M -$1.190M
YoY Change
Total Liabilities & Shareholders Equity $51.60M $23.99M
YoY Change 11.96% -62.03%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$7.488M -$6.786M
YoY Change -17.74% -24.15%
Depreciation, Depletion And Amortization $85.00K $88.00K
YoY Change -60.83% -56.22%
Cash From Operating Activities -$6.175M -$6.480M
YoY Change -4.69% -28.57%
INVESTING ACTIVITIES
Capital Expenditures $7.000K $0.00
YoY Change -98.03% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$7.000K $0.00
YoY Change -98.03% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 34.35M 20.00K
YoY Change -826.81% -94.29%
NET CHANGE
Cash From Operating Activities -6.175M -6.480M
Cash From Investing Activities -7.000K 0.000
Cash From Financing Activities 34.35M 20.00K
Net Change In Cash 28.17M -6.460M
YoY Change -343.64% -26.84%
FREE CASH FLOW
Cash From Operating Activities -$6.175M -$6.480M
Capital Expenditures $7.000K $0.00
Free Cash Flow -$6.182M -$6.480M
YoY Change -9.55% -27.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001544227
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35890
dei Entity Registrant Name
EntityRegistrantName
Tempest Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-1472564
dei Entity Address Address Line1
EntityAddressAddressLine1
2000 Sierra Point Parkway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
Brisbane
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94005
dei City Area Code
CityAreaCode
(415)
dei Local Phone Number
LocalPhoneNumber
798-8589
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19247495
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11118000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31230000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
450000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1173000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1270000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
12291000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
32950000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
921000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1060000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10382000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11650000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
393000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
429000
CY2023Q3 us-gaap Assets
Assets
23987000
CY2022Q4 us-gaap Assets
Assets
46089000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1139000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1108000
CY2022Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
450000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1995000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2961000
CY2023Q3 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
65000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2134000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1117000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1413000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
931000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1248000
CY2023Q3 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
106000
CY2022Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
97000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7422000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7277000
CY2023Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
255000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
454000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8371000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10371000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9384000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10330000
CY2023Q3 us-gaap Liabilities
Liabilities
25177000
CY2022Q4 us-gaap Liabilities
Liabilities
27978000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14323405
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14323405
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10518539
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10518539
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
14000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
156571000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
153872000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-157775000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135772000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1190000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
18111000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23987000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46089000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4221000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5973000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
13315000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
16733000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2371000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2798000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8328000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8973000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6592000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8771000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21643000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25706000
CY2023Q3 us-gaap Interest Expense
InterestExpense
373000
CY2022Q3 us-gaap Interest Expense
InterestExpense
389000
us-gaap Interest Expense
InterestExpense
1072000
us-gaap Interest Expense
InterestExpense
1186000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
179000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
213000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
712000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
286000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-194000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-176000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-360000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-900000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-6786000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-8947000
us-gaap Profit Loss
ProfitLoss
-22003000
us-gaap Profit Loss
ProfitLoss
-26606000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.46
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14121805
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14121805
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13635927
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13635927
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14059008
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14059008
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10815900
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10815900
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
18111000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
44000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
446000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7636000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10965000
CY2023Q2 tpst Stock Issuance Costs
StockIssuanceCosts
30000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1186000
CY2023Q2 tpst Exercise Of Pre Funded Warrants
ExerciseOfPreFundedWarrants
1000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
440000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7581000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5012000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20000
CY2023Q3 tpst Exercise Of Pre Funded Warrants
ExerciseOfPreFundedWarrants
1000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
563000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6786000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1190000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
36117000
CY2022Q1 tpst Stock Issuance Costs
StockIssuanceCosts
44000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1403000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
328000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-8491000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
29357000
CY2022Q2 tpst Stock Issuance Costs
StockIssuanceCosts
343000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7095000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
367000
CY2022Q2 tpst Warrant Issuance Costs
WarrantIssuanceCosts
283000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7281000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9168000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
34932000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
4000
CY2022Q3 tpst Stock Issuance Costs
StockIssuanceCosts
111000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
350000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
438000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8947000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
26773000
us-gaap Profit Loss
ProfitLoss
-22003000
us-gaap Profit Loss
ProfitLoss
-26606000
us-gaap Depreciation
Depreciation
296000
us-gaap Depreciation
Depreciation
421000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1449000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1133000
tpst Noncash Lease Expense
NoncashLeaseExpense
1268000
tpst Noncash Lease Expense
NoncashLeaseExpense
854000
tpst Noncash Interest And Other Expense Net
NoncashInterestAndOtherExpenseNet
142000
tpst Noncash Interest And Other Expense Net
NoncashInterestAndOtherExpenseNet
267000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-152000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
336000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
28000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-89000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1281000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
946000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
9000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
27000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1242000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1210000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21182000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24593000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
163000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
206000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-163000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-206000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1253000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8849000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
7280000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1253000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16129000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20092000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8670000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31598000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51829000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11506000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43159000
us-gaap Interest Paid Net
InterestPaidNet
927000
us-gaap Interest Paid Net
InterestPaidNet
893000
us-gaap Income Taxes Paid
IncomeTaxesPaid
152000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
884000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
3000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.</span></p>
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
751000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
703000
CY2023Q3 tpst Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
190000
CY2022Q4 tpst Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
304000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
232000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
263000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1173000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1270000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2573000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2421000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1652000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1361000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
921000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1060000
CY2023Q3 us-gaap Depreciation
Depreciation
88000
us-gaap Depreciation
Depreciation
296000
CY2022Q3 us-gaap Depreciation
Depreciation
201000
us-gaap Depreciation
Depreciation
421000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
953000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
756000
CY2023Q3 tpst Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
1042000
CY2022Q4 tpst Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
2205000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1995000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2961000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1553041
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
679150
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
10500000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14323405
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14323405
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10518539
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10518539
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.29
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
413
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
50193
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.36
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2181585
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.04
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
790637
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
903527
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.35
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
56235
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
266.8
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1637929
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.72
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2181585
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M7D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.04
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2181585
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y3M7D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
5.04
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
923411
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M25D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.71
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.46
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
563000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
438000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1449000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1133000
CY2023Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
31000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
122000
CY2022Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
39000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6786000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8947000
us-gaap Net Income Loss
NetIncomeLoss
-22003000
us-gaap Net Income Loss
NetIncomeLoss
-26606000
CY2023Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
14121805
CY2022Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
13635927
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
14059008
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
10815900
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14121805
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14121805
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13635927
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13635927
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14059008
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14059008
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10815900
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10815900
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.57
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2312621
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1643965

Files In Submission

Name View Source Status
R13.htm Edgar Link pending
R14.htm Edgar Link pending
0000950170-23-061278-index-headers.html Edgar Link pending
0000950170-23-061278-index.html Edgar Link pending
0000950170-23-061278.txt Edgar Link pending
0000950170-23-061278-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tpst-20230930.htm Edgar Link pending
tpst-20230930.xsd Edgar Link pending
tpst-ex10_1.htm Edgar Link pending
tpst-ex31_1.htm Edgar Link pending
tpst-ex31_2.htm Edgar Link pending
tpst-ex32_1.htm Edgar Link pending
tpst-20230930_pre.xml Edgar Link unprocessable
tpst-20230930_lab.xml Edgar Link unprocessable
tpst-20230930_htm.xml Edgar Link completed
tpst-20230930_def.xml Edgar Link unprocessable
tpst-20230930_cal.xml Edgar Link unprocessable